Antineoplastics - Arsenic Compounds

Antineoplastics – Arsenic Compounds is a specialized therapeutic subclass of antineoplastic agents consisting of arsenic-based compounds, primarily represented in clinical practice by arsenic trioxide The primary established therapeutic indication for this class is acute promyelocytic leukemia, utilized in both frontline regimens alongside tretinoin and for relapsed or refractory disease

Antineoplastics – Arsenic Compounds is a specialized therapeutic subclass of antineoplastic agents consisting of arsenic-based compounds, primarily represented in clinical practice by arsenic trioxide

These agents exert antineoplastic activity by inducing morphological changes, promoting oxidative stress, generating reactive oxygen species, and triggering programmed cell death (apoptosis) in malignant cells

These agents exert antineoplastic activity by inducing morphological changes, promoting oxidative stress, generating reactive oxygen species, and triggering programmed cell death (apoptosis) in malignant cells Additionally, they facilitate the degradation of the pathognomonic promyelocytic leukemia–retinoic acid receptor alpha (PML-RARα) fusion protein, thereby restoring myeloid cell differentiation

These agents exert antineoplastic activity by inducing morphological changes, promoting oxidative stress, generating reactive oxygen species, and triggering programmed cell death (apoptosis) in malignant cells Additionally, they facilitate the degradation of the pathognomonic promyelocytic leukemia–retinoic acid receptor alpha (PML-RARα) fusion protein, thereby restoring myeloid cell differentiation

The primary established therapeutic indication for this class is acute promyelocytic leukemia, utilized in both frontline regimens alongside tretinoin and for relapsed or refractory disease